Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 287

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 287
---
’s business, financial condition, results of operations and prospects. Any third-party CMOs and suppliers Kineta engages will also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on Kineta’s business, financial condition, results of operations and prospects. Risks Relating to Kineta’s Common Stock The price of Kineta Common Stock may be volatile or may decline regardless of its operating performance. The trading price of the common stock will be volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond Kineta’s control. These factors include:

| • |     | actual or anticipated fluctuations in operating results; |

| • |     | failure to meet or exceed financial estimates and projections of the investment community or that Kineta provides to the public; |

| • |     | issuance of new or updated research or reports by securities analysts or changed recommendations for the industry in general; |

169

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; |

| • |     | operating and share price performance of other companies in the industry or related markets; |

| • |     | the timing and magnitude of investments in the growth of the business; |

| • |     | actual or anticipated changes in laws and regulations; |

| • |     | additions or departures of key management or other personnel; |

| • |     | increased labor costs; |

| • |     | disputes or other developments related to intellectual property or other proprietary rights, including litigation; |

| • |     | the ability to market new and enhanced solutions on a timely basis; |

| • |     | sales of substantial amounts of common stock by Kineta’s directors, executive officers or significant stockholders or the perception that such sales could occur; |

| • |     | changes in capital structure, including future issuances of securities or the incurrence of debt; and |

| • |     | general economic, political and market conditions. |

In addition, the stock market in general, and the stock prices of bio-pharmaceuticaland biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of common stock, regardless of actual operating performance. In addition, in the past,